Can Older Breast Cancer Patients Tolerate Immunotherapy Plus Chemotherapy?
Using a newer combination of immunotherapy and lower doses of chemotherapy, USC Norris Comprehensive Cancer Center experts treated a 79-year-old woman with triple-negative breast cancer.
Clinical Scorecard: Can Older Breast Cancer Patients Tolerate Immunotherapy Plus Chemotherapy?
At a Glance
Category Detail
Condition Triple-Negative Breast Cancer Key Mechanisms Combination of immunotherapy (pembrolizumab) and lower doses of chemotherapy Target Population Older patients, particularly those over 75 years old Care Setting Oncology clinics, specifically for older adults
Key Highlights
Triple-negative breast cancer is aggressive and has a high recurrence rate. Lower doses of chemotherapy can improve tolerability in older patients. Close monitoring of side effects is crucial for older patients undergoing treatment. Complete pathologic response correlates with better overall survival rates. Circulating tumor cell tests are more effective for early detection of recurrence. Guideline-Based Recommendations
Diagnosis
Consider age and comorbidities when diagnosing and treating older patients. Management
Use lower doses of chemotherapy and immunotherapy for older patients. Administer chemotherapy weekly for better monitoring. Monitoring & Follow-up
Monitor blood cell counts and side effects closely during treatment. Risks
Older patients may have increased side effects from chemotherapy. Patient & Prescribing Data
Older patients, particularly those over 75 with comorbidities.
Adjust chemotherapy doses and closely monitor for side effects.
Clinical Best Practices
Modify chemotherapy regimens based on patient age and health status. Utilize circulating tumor cell tests for monitoring recurrence. References
